The short answer
Deferasirox can increase caffeine exposure. The sources support discussing caffeine supplements with the treatment team and individualized limits and clinical monitoring during co-use; spacing the doses has not been shown to prevent this effect.
What this answer covers
Applies to oral systemic deferasirox with concentrated caffeine supplements.
- Supplement or preparation
- Caffeine
- Medication ingredient
- deferasirox
Evidence and practical considerations
Timing & monitoring
Because deferasirox increases caffeine exposure, exact labeling supports limitation and clinical monitoring. The medication-to-supplement direction is explicit and is applicable to Q4 management only; the mechanism is metabolic inhibition, so separation in time is not a validated solution.
- Exact scope
- caffeine-containing dietary supplements with deferasirox
- Medication form and route
- oral systemic deferasirox with concentrated caffeine supplements
- Timing or duration
- Monitoring applies throughout co-use; dose separation does not negate CYP1A2 inhibition.
What remains uncertain
- No evidence supports an hour-based separation interval.
- Limitation should be individualized rather than a universal ban.
- The causal pharmacokinetic direction is deferasirox-to-caffeine; this record is retained under Q4 only because Q4 captures co-use requirements, not as a Q3 supplement-to-medication toxicity finding.
Factors that may matter: caffeine dose; cardiac disease; sleep disorder; other stimulants.
Read the supporting source summaries
Source 1: current United States prescribing information
dailymed.nlm.nih.gov · Source check Jul 25, 2026
Population: Patients receiving deferasirox with caffeine or other CYP1A2 substrates.
The label instructs close monitoring when deferasirox is used with caffeine and other CYP1A2 substrates.
No universal caffeine limit is given.
Source 2: United States government patient drug information
medlineplus.gov · Source check Jul 25, 2026
Population: Patients taking deferasirox.
MedlinePlus names caffeine supplements and directs disclosure to clinicians.
No quantified limit or separation interval.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Research summary published |
Article revision: 9a8458ceeec54db2
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.